Product Information

TACROLIMUS 5 MG CAPSULE (IMMEDIATE RELEASE) is a generic product labeled by Quallent Pharmaceuticals Health LLC, priced at $0.6658 per EA under NDC 82009016501. Its NADAC has been published 67 times since Aug 13, 2025.

FDA first approved this application on May 12, 2010. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

TACROLIMUS 5 MG CAPSULE (IMMEDIATE RELEASE)

Tacrolimus
$0.6658per EA

Strength

5 mg/1

NDC

82009016501

Classification

Generic

Dosage Form

CAPSULE

Route

ORAL

Effective Date

11/18/2026

Active Ingredients

TACROLIMUS

Approval Type

Generic (ANDA)

FDA Application

ANDA090509

FDA Approved

5/12/2010

TE Code

AB

On Market Since

6/1/2025

Pharmacological Classes

Price Statistics

The NADAC for TACROLIMUS 5 MG CAPSULE (IMMEDIATE RELEASE) has been published 67 times since Aug 13, 2025, and over the history we have for it it has declined 27.9%. The table below summarizes its recorded NADAC range and movement.

Current price$0.6658 per EA
All-time high$0.9230 (Aug 13, 2025)
All-time low$0.6505 (Jun 17, 2026)
52-week high$0.8041
52-week low$0.6505
Median price$0.7030
Average price$0.7305
Largest weekly change-6.4% (Aug 20, 2025)
Weeks tracked67
Tracking sinceAug 13, 2025

Price History

1W

-3.2%

1M

-3.2%

3M

+1.0%

6M

-1.3%

1Y

-19.4%

3Y

N/A

5Y

N/A

All

-27.9%

Generic Alternatives

The matcher finds 12 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Continue researching this drug

Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.

Frequently asked questions

What is the NADAC price of TACROLIMUS 5 MG CAPSULE (IMMEDIATE RELEASE)?

The current National Average Drug Acquisition Cost (NADAC) for TACROLIMUS 5 MG CAPSULE (IMMEDIATE RELEASE), manufactured by Quallent Pharmaceuticals Health LLC, is $0.6658 per EA (NDC 82009016501), effective Nov 18, 2026.

How has the price of TACROLIMUS 5 MG CAPSULE (IMMEDIATE RELEASE) changed over time?

Over the history we have for it, the NADAC for TACROLIMUS 5 MG CAPSULE (IMMEDIATE RELEASE) has declined 27.9%. It has been tracked across 67 weekly CMS publications since Aug 13, 2025.

What are the highest and lowest recorded NADAC prices for TACROLIMUS 5 MG CAPSULE (IMMEDIATE RELEASE)?

Since Aug 13, 2025, the NADAC for TACROLIMUS 5 MG CAPSULE (IMMEDIATE RELEASE) has ranged from a low of $0.6505 (Jun 17, 2026) to a high of $0.9230 (Aug 13, 2025), with a median of $0.7030 per EA.

Are there cheaper alternatives to TACROLIMUS 5 MG CAPSULE (IMMEDIATE RELEASE)?

12 manufacturers publish a NADAC-priced product with the same active ingredient and strength as TACROLIMUS 5 MG CAPSULE (IMMEDIATE RELEASE) in a comparable dosage form, but none are currently priced below it.

Who manufactures TACROLIMUS 5 MG CAPSULE (IMMEDIATE RELEASE)?

TACROLIMUS 5 MG CAPSULE (IMMEDIATE RELEASE) (NDC 82009016501) is labeled by Quallent Pharmaceuticals Health LLC, and CMS classifies it as a generic product.